MedTrace Logo

Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC

NCT04768491 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 82

Last updated 2021-02-24

No results posted yet for this study

Summary

This is a non-interventional, multi-center, ambispective cohort study in real world to describe the effectiveness and safety profile in patients with EGFR mutation-positive advanced NSCLC treated with dacomitinib (Vizimpro®) as the first-line treatment followed by 3rd generation EGFR-TKI in case the T790M resistance mutation was developed.

Conditions

  • EGFR Activating Mutation
  • NSCLC Stage IV
  • NSCLC Stage IIIB
  • NSCLC, Recurrent

Interventions

DRUG

Dacomitinib

effectiveness and safety profile in patients with EGFR mutation-positive advanced NSCLC treated with dacomitinib (Vizimpro®) as the first-line treatment followed by 3rd generation EGFR-TKI in case the T790M resistance mutation was developed.

Sponsors & Collaborators

  • Peking Union Medical College

    lead OTHER

Principal Investigators

  • Junling Li, MD · Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2024-06-30
Completion
2024-10-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04768491 on ClinicalTrials.gov